[Comments about "Management of aspergillosis in immunocompromised patients. Recommendations of Lille University Hospital--4th version--November 2004"].
Mahi
L
L
D000935:Antifungal Agents / Q000627:therapeutic use*; D001228:Aspergillosis / Q000188:drug therapy* / Q000276:immunology; D019090:Case Management; D000077336:Caspofungin; D002986:Clinical Trials as Topic; D054714:Echinocandins; D006801:Humans; D016867:Immunocompromised Host; D055666:Lipopeptides; D010456:Peptides, Cyclic / Q000627:therapeutic use*; D017410:Practice Guidelines as Topic
D000935:Antifungal Agents; D054714:Echinocandins; D055666:Lipopeptides; D010456:Peptides, Cyclic; D000077336:Caspofungin